/4882.T
4882.T Stock - Perseus Proteomics Inc.
Healthcare|Drug Manufacturers - GeneralJPX
$220.00+5.77%
+$12.00 (+5.77%) • Dec 24
55
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $242.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for 4882.T
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$217.80 – $222.20
TARGET (TP)$253.00
STOP LOSS$202.40
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.44
52W High$1113.00
52W Low$203.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $120.38M | $100.40M | $94.20M | $71.93M | $67.95M |
| Gross Profit | $104.05M | $87.69M | $86.53M | $67.75M | $64.10M |
| Gross Margin | 86.4% | 87.3% | 91.9% | 94.2% | 94.3% |
| Operating Income | $-829,701,000 | $-894,729,000 | $-697,769,000 | $-472,195,000 | $-411,749,000 |
| Net Income | $-904,800,000 | $-1,104,460,000 | $-786,999,000 | $-599,023,000 | $-413,216,000 |
| Net Margin | -751.7% | -1100.0% | -835.4% | -832.8% | -608.1% |
| EPS | $-63.41 | $-93.69 | $-66.93 | $-54.47 | $-59.03 |
Company Overview
Perseus Proteomics Inc., a drug discovery biotech venture company, develops antibody drugs against cancer and other diseases in Japan. The company is involved in the antibody discovery activities; and antibody research support activities comprising hybridoma antibody sequencing, antibody protein production, and contract antibody research activities, as well as supply of antibody products. Its product pipeline includes PPMX-T001, an anti-hepatocarcinoma antibody; PPMX-T002, an anticancer drug; PPMX-T003, a drug for the treatment of adult T-cell; and PPMX-T004, an antibody drug conjugate. The company was incorporated in 2001 and is headquartered in Tokyo, Japan.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
4882.TBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-13.79
Q4 2025
EPS Surprise History
Q4 23
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
No data
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 14, 2026 | — | — | — | — |
Q4 2025 | Nov 14, 2025 | — | $-13.79 | — | — |
Q3 2025 | Aug 18, 2025 | — | $-11.94 | — | — |
Q2 2025 | May 15, 2025 | — | $-14.28 | — | — |
Q1 2025 | Feb 14, 2025 | — | $-13.50 | — | — |
Q4 2024 | Nov 14, 2024 | — | $-18.72 | — | — |
Q3 2024 | Aug 14, 2024 | — | $-17.04 | — | — |
Q2 2024 | May 15, 2024 | — | $-17.28 | — | — |
Q4 2023 | Dec 31, 2023 | — | $-22.59 | — | — |
Q4 2023 | Nov 13, 2023 | — | $-17.97 | — | — |
Q3 2023 | Aug 14, 2023 | — | $-35.90 | — | — |
Q2 2023 | May 12, 2023 | — | $-19.11 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-16.92 | — | — |
Q4 2022 | Nov 11, 2022 | — | $-13.84 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-13.84 | — | — |
Q2 2022 | May 13, 2022 | — | — | — | — |
Q1 2022 | Feb 14, 2022 | — | — | — | — |
Latest News
Loading news...
Frequently Asked Questions about 4882.T
What is 4882.T's current stock price?
Perseus Proteomics Inc. (4882.T) is currently trading at $220.00 per share. The stock has moved +5.77% today.
What is the analyst price target for 4882.T?
No analyst price targets are currently available for this stock.
What sector is Perseus Proteomics Inc. in?
Perseus Proteomics Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - General industry. The company is traded on the JPX exchange.
What is 4882.T's market cap?
Perseus Proteomics Inc. has a market capitalization of $3.24 billion, making it a mid-cap company.
Does 4882.T pay dividends?
No, Perseus Proteomics Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare Sector4570.T
Immuno-Biological Laboratories Co., Ltd.
$1404.00
Mkt Cap: $13.1B
4572.T
Carna Biosciences, Inc.
$415.00
Mkt Cap: $7.9B
4576.T
D. Western Therapeutics Institute, Inc.
$93.00
Mkt Cap: $4.1B
4591.T
Ribomic Inc.
$74.00
Mkt Cap: $3.5B
4596.T
Kubota Pharmaceutical Holdings Co., Ltd.
$42.00
Mkt Cap: $2.5B
4598.T
Delta-Fly Pharma, Inc.
$500.00
Mkt Cap: $5.7B
4881.T
FunPep Company Limited
$77.00
Mkt Cap: $3.1B
4892.T
Cyfuse Biomedical K.K.
$588.00
Mkt Cap: $5.2B
7037.T
teno. Holdings Company Limited
$964.00
Mkt Cap: $4.4B
7091.T
Living Platform,Ltd.
$1008.00
Mkt Cap: $4.5B
Explore stocks similar to 4882.T for comparison